PGR and breast carcinoma: Furthermore, we have shown the therapy resistance of the TNBC line MDA-MB-231 over the estrogen- and progesterone receptor-positive line MCF7, although we failed to advance our understanding of differences in sensitivity to chemotherapy among different types of breast cancers.